Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

Kevin Tyan, Ji Eun Bae, Jochen H. Lorch, Danielle N. Margalit, Roy B. Tishler, Mai Anh Huynh, Vickie Y. Jo, Robert I. Haddad, Nicole G. Chau, Glenn J. Hanna, Jonathan D. Schoenfeld*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.

Original languageEnglish (US)
Pages (from-to)722-734
Number of pages13
JournalHead and Neck
Issue number3
StatePublished - Mar 2022
Externally publishedYes


  • adenoid cystic carcinoma
  • head and neck neoplasms
  • locally ablative therapy
  • oligometastatic
  • survival
  • systemic therapy
  • treatment interval
  • tumor burden

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes'. Together they form a unique fingerprint.

Cite this